Buchi Neita, PA-C

Trickett and Neita discuss shared decision-making in HS, investigational ruxolitinib cream and upadacitinib data, and how to counsel on JAK inhibitor boxed warnings.

Trickett and Neita compare adalimumab, secukinumab, and bimekizumab trial data and explain how comorbidities guide biologic selection in hidradenitis suppurativa.